Cancer Clinical | Sebastian Zekihttps://www.sebastianzeki.co.uk/tag/cancer-clinical/Cancer ClinicalSource Themes Academic (https://sourcethemes.com/academic/)en-usWed, 01 Jan 2025 00:00:00 +0000https://www.sebastianzeki.co.uk/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_2.pngCancer Clinicalhttps://www.sebastianzeki.co.uk/tag/cancer-clinical/Development of a symptom response to treatment questionnaire for patients in follow-up after oesophago-gastrectomy for cancerhttps://www.sebastianzeki.co.uk/publication/orcid_development-of-a-symptom-response-to-treatment-questionnaire/Wed, 01 Jan 2025 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_development-of-a-symptom-response-to-treatment-questionnaire/Prehabilitation of Patients With Oesophageal Malignancy Undergoing Peri-Operative Treatment (Pre-EMPT): Outcomes From a Prospective Controlled Trialhttps://www.sebastianzeki.co.uk/publication/orcid_prehabilitation-of-patients-with-oesophageal-malignancy-unde/Wed, 01 Jan 2025 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_prehabilitation-of-patients-with-oesophageal-malignancy-unde/REsolution of Symptoms afTer Oesophago-gastric cancer REsection delphi (RESTOREd)—standardizing the definition, investigation and management of gastrointestinal symptoms and conditions after surgeryhttps://www.sebastianzeki.co.uk/publication/orcid_resolution-of-symptoms-after-oesophago-gastric-cancer-resect/Mon, 01 Jan 2024 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_resolution-of-symptoms-after-oesophago-gastric-cancer-resect/Association of dynamic contrast-enhanced MRI and <sup>18</sup>F-Fluorodeoxyglucose PET/CT parameters with neoadjuvant therapy response and survival in esophagogastric cancerhttps://www.sebastianzeki.co.uk/publication/orcid_association-of-dynamic-contrast-enhanced-mri-and-sup18supf-f/Sun, 01 Jan 2023 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_association-of-dynamic-contrast-enhanced-mri-and-sup18supf-f/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1016/j.ejso.2023.05.009"></div>Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinomahttps://www.sebastianzeki.co.uk/publication/orcid_metabolic-tumour-and-nodal-response-to-neoadjuvant-chemother/Sun, 01 Jan 2023 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_metabolic-tumour-and-nodal-response-to-neoadjuvant-chemother/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1007/s00330-023-09482-7"></div>Multiple staging investigations may not change management in patients with high-grade dysplasia or early esophageal adenocarcinomahttps://www.sebastianzeki.co.uk/publication/orcid_multiple-staging-investigations-may-not-change-management-in/Sun, 01 Jan 2023 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_multiple-staging-investigations-may-not-change-management-in/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1093/dote/doad020"></div>Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdomhttps://www.sebastianzeki.co.uk/publication/orcid_pathologic-lymph-node-regression-after-neoadjuvant-chemother/Sun, 01 Jan 2023 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_pathologic-lymph-node-regression-after-neoadjuvant-chemother/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1200/JCO.23.00139"></div>Clinical Relevance of the Tumor Location-Modified Laurén Classification System for Gastric Cancer in a Western Populationhttps://www.sebastianzeki.co.uk/publication/orcid_clinical-relevance-of-the-tumor-location-modified-lauren-cla/Sat, 01 Jan 2022 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_clinical-relevance-of-the-tumor-location-modified-lauren-cla/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1245/s10434-021-11252-y"></div>Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma – A comparison of the FLOT and ‘MAGIC’ regimenshttps://www.sebastianzeki.co.uk/publication/orcid_effect-of-peri-operative-chemotherapy-regimen-on-survival-in/Sat, 01 Jan 2022 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_effect-of-peri-operative-chemotherapy-regimen-on-survival-in/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1016/j.ejca.2021.12.021"></div>Patient perspectives on key symptoms and preferences for follow-up after upper gastro-intestinal cancer surgeryhttps://www.sebastianzeki.co.uk/publication/orcid_patient-perspectives-on-key-symptoms-and-preferences-for-fol/Sat, 01 Jan 2022 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_patient-perspectives-on-key-symptoms-and-preferences-for-fol/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1007/s00520-022-06922-w"></div>Does a high Mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma?https://www.sebastianzeki.co.uk/publication/orcid_does-a-high-mandard-score-really-define-a-poor-response-to-c/Fri, 01 Jan 2021 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_does-a-high-mandard-score-really-define-a-poor-response-to-c/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1038/s41416-021-01290-4"></div>Initial experience in staging primary oesophageal/gastro-oesophageal cancer with 18F-FDG PET/MRIhttps://www.sebastianzeki.co.uk/publication/orcid_initial-experience-in-staging-primary-oesophagealgastro-oeso/Fri, 01 Jan 2021 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_initial-experience-in-staging-primary-oesophagealgastro-oeso/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1186/s41824-021-00117-y"></div>Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection marginhttps://www.sebastianzeki.co.uk/publication/orcid_adjuvant-therapy-following-oesophagectomy-for-adenocarcinoma/Wed, 01 Jan 2020 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_adjuvant-therapy-following-oesophagectomy-for-adenocarcinoma/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1016/j.soc.2004.06.008"></div>Machine learning to predict early recurrence after oesophageal cancer surgeryhttps://www.sebastianzeki.co.uk/publication/orcid_machine-learning-to-predict-early-recurrence-after-oesophage/Wed, 01 Jan 2020 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_machine-learning-to-predict-early-recurrence-after-oesophage/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1002/bjs.11461"></div>Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagushttps://www.sebastianzeki.co.uk/publication/orcid_prediction-of-a-positive-circumferential-resection-margin-at/Tue, 01 Jan 2019 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_prediction-of-a-positive-circumferential-resection-margin-at/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1002/bjs5.50211"></div>Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinomahttps://www.sebastianzeki.co.uk/publication/orcid_lymph-node-regression-and-survival-following-neoadjuvant-che/Mon, 01 Jan 2018 00:00:00 +0000https://www.sebastianzeki.co.uk/publication/orcid_lymph-node-regression-and-survival-following-neoadjuvant-che/<div class="altmetric-embed" data-badge-type="donut" data-badge-popover="right" data-doi="10.1002/bjs.10900"></div>